Back to Stakeholders
Categories

4 domains / 10 areas / 8 specializations

Care Delivery & Psychedelic Facilitation
Care Delivery & Psychedelic Facilitation
Non-Clinical, Spiritual & Facilitation ModelsRetreat Organizations
Psychedelic Healthcare ImplementationHealth Economists
Media, Education & Engagement
Educational Platforms & ResourcesOnline Resources
Media & CommunicationConferences & EventsPodcasts & Broadcast Media
Media, Education & Engagement
Government, Policy & Advocacy
Government, Policy & Advocacy
Policy Advocacy & ReformCaucuses & Working GroupsIndustry Associations & Lobby Groups
Community & Cultural Stakeholders
Community & Cultural Stakeholders
Community Networks & OutreachCommunity Outreach & Education Programs

MAPS

12 Trials2 Papers

Nonprofit organizer and host of the Psychedelic Science conference series, alongside broader educational and policy programming.

Community Networks & Outreach Snapshot

Organization Model

Not set

Organization Status

Not set

Psychedelic Focus

Not set

Last Verified

Apr 17, 2026

Engagement Channels

Engagement channels not set yet.

Audience Focus

Audience focus not set yet.

Verification

Verified

Jurisdiction

Not set

Coverage

Coverage not set

Verification Notes

Seeded from curated community.xlsx list; requires source-level verification pass. Wave 3 web verification (2026-04-17): detected terms [psychedelic, psychedelics, ayahuasca, ibogaine, mdma, harm reduction, community, peer support] on https://maps.org/.

Primary Community Link

Sources

Official website

https://maps.org/

Reimbursement & Market Access Snapshot

This stakeholder is tagged in Reimbursement & Market Access, but profile details have not been added yet.

Quick Facts

Type
nonprofit
Website
Visit

Sponsored Trials

3
WithdrawnII

Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma

Start Date
Compounds
Psilocybin
CompletedII

Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety

Start Date
Compounds
LSD
TerminatedI

MDMA-Assisted Psychotherapy Low-Dose Pilot for Chronic PTSD: Double-Blind RCT (Bouso / Doblin / Farré, Madrid Spain 2000–2002)

Start Date
Compounds
MDMA, Placebo

Collaborated Trials

9
RecruitingI

MDMA-assisted Therapy for Fibromyalgia

Start Date
Compounds
MDMA
RecruitingII

MDMA for Co-occurring PTSD and OUD After Childbirth

Start Date
Compounds
MDMA
Unknown statusII

Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury

Start Date
Compounds
MDMA
CompletedII

Social Anxiety MDMA-Assisted Therapy Investigation (SAMATI)

Start Date
Compounds
MDMA
CompletedII

A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)

Start Date
Compounds
MDMA
CompletedII

MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD

Start Date
Compounds
MDMA
CompletedII

Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification

Start Date
Compounds
Ibogaine
CompletedII

Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study

Start Date
Compounds
MDMA
CompletedIII

Epigenetics and MDMA-Assisted Psychotherapy for PTSD

Start Date
Compounds
MDMA, Placebo

Research Papers

2
Open AccessindividualPooled analysis

Long-term Follow-Up Outcomes of MDMA-assisted Psychotherapy for Treatment of PTSD: A Longitudinal Pooled Analysis of Six Phase 2 Trials

Pooled analysis of six phase 2 trials found that two to three MDMA‑assisted psychotherapy sessions produced large reductions in PTSD severity at 1–2 months (LS mean change −44.8; Cohen’s d = 1.58) with further small but significant improvement at least 12 months post‑treatment (LS mean change −5.2; d = 0.23). The proportion no longer meeting PTSD criteria rose from 56% at treatment exit to 67% at long‑term follow‑up, most participants reported lasting benefits (improved relationships and well‑being) and only a minority reported harms; phase 3 trials are underway to confirm these results.

Published
Journal
Psychopharmacology
Authors
Jerome, L., Feduccia, A. A., Wang, J. B., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., Doblin, R.
Open Accessmeta

Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline

This review (2019) details the potential superiority of MDMA-assisted psychotherapy as a treatment for PTSD compared to the conventional treatment options paroxetine and sertraline.

Published
Journal
Frontiers in Psychiatry
Authors
Feduccia, A. A., Jerome, L., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., Doblin, R.